Andrew is ranked in Tier 1 for mid-market M&A by both Chambers UK and legal 500 directories as well as being listed as one of The Lawyer's Hot 100. Andrew's clients describe him as 'a strong negotiator and problem solver' as well as 'fast and pragmatic and able to understand our needs very well'.

He has particular expertise in the Life Sciences sector and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries. Andrew has a wealth of expertise in Indian and Russian M&A, having acted on some of the largest multi-billion dollar transactions to have taken place in those jurisdictions.

Whilst at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

CV ansehen CV ausblenden

Aktuelle News & Insights

Life Sciences & Healthcare

Advising Apollo Therapeutics on $145 million financing

21. Juni 2021

von Andrew Edge und Chris Cowley

Klicken Sie hier für Details
China Projekte (inbound / outbound)

China’s system of negative lists explained

China In & Out

22. Juli 2021

von Kai Schlender, M.A.

Klicken Sie hier für Details
Gesellschaftsrecht/ M&A & Kapitalmärkte

Taylor Wessing berät Hardinge, Inc. beim Erwerb der WEISSER Gruppe

21. Juli 2021

von mehreren Autoren

Klicken Sie hier für Details
turboliquidatie
Gesellschaftsrecht/ M&A & Kapitalmärkte

Dutch Minister proposes new temporary expedited liquidation rules

15. Juli 2021
Briefing

von Maja Bolè und Mark Goorts

Klicken Sie hier für Details

Meet me at

Alle Veranstaltungen und Webinare finden Sie auf unserer Event-Seite.